Compare Incyte Corporation (INCY) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs J B Hunt Transport Services Inc — how do they compare? Incyte Corporation trades at $113.14 (market cap $22.85B), while J B Hunt Transport Services Inc trades at $228.6 (market cap $21.45B). The key difference: Incyte Corporation and J B Hunt Transport Services Inc are close in size by market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and J B Hunt Transport Services Inc for 45 Days on average.
| INCY | JBHT | |
|---|---|---|
Market Cap | $22.85B | $21.45B |
Volume | 1,927,029 | 1,028,680 |
Sector | Health | Industrials |
52-Week High | $129.93 | $298.41 |
52-Week Low | $83.80 | $137.09 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $18.35B | $22.59B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
JBHT trades at $228.99, up 2.85% today, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $12.00B in 2025, with a net income margin of 4.98%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $289.40 price target, but news highlights ongoing securities class action investigations.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and legal risks pose headwinds. Investors should weigh earnings growth potential against cost pressures and litigation uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
